¸¶»ÒÎÏ´ðÈ×µ»½Ñ¥Ç¡¼¥¿¥Ù¡¼¥¹¤Î¥á¥¤¥ó¥Ú¡¼¥¸¤Ø

ºîÀ®¡§ 1999/02/01 ÎëÌÚ¡¡ÏÂÃË

¥Ç¡¼¥¿Èֹ桡¡¡¡¡¡§150012
Êü¼ÍÀþÈïÇø¤Ë¤è¤ë¼«¸ÊÌȱּÀ´µ¤ÎͶȯ¤Ë´ØÏ¢¤¹¤ë¹¥Ãæµå¥ß¥¨¥í¥Ñ¡¼¥ª¥­¥·¥Ç¡¼¥¹¤Îʬ»Ò¹½Â¤¤ÎÊѲ½¤È¤½¤ÎÀ­¾õ
ÌÜŪ¡¡¡¡¡¡¡¡¡¡¡¡¡§Êü¼ÍÀþÈïÇø¤Ë¤è¤ë¼«¸ÊÌȱּÀ´µ¤ÎͶȯ¤Ë´ØÏ¢¤¹¤ë¤ÈͽÁÛ¤µ¤ì¤ë¹¥Ãæµå¹ÚÁǥߥ¨¥í¥Ñ¡¼¥ª¥­¥·¥Ç¡¼¥¹¤ÎÊü¼ÍÀþ´¶¼õÀ­¤Ë¤Ä¤¤¤Æ¤Î¸¦µæ¤Î¸½¾õ¤òÇÄ°®¤¹¤ë¡£
¸¦µæ¼Â»Üµ¡´Ø̾¡¡¡§¹ñΩ´¶À÷¾É¸¦µæ½ê¡¡À¸Êª³èÀ­Êª¼ÁÉô¡¡À¸ÂÎËɸæʪ¼Á¼¼
±þÍÑʬÌî¡¡¡¡¡¡¡¡¡§Êü¼ÍÀþ¤Ë¤è¤ëÃÁÇòʬ»Ò¤ÎÃÇÊÒ²½¡¢¼«¸ÊÌȱּÀ´µ¤Î¿ÇÃÇ

³µÍס¡¡¡¡¡¡¡¡¡¡¡¡§
¡¡Myeloperoxidase(MPO)¤ÎÃÇÊÒ²½¤Ï¡¢FMLP(fMet-Leu-Phe)»É·ã¤Ë¤è¤ë³èÀ­²½¤Ë¤è¤Ã¤ÆÀ¸¤¸¤ë¤ÈͽÁÛ¤µ¤ì¤¿¤³¤È¤«¤é¡¢¦ÃÀþ¾È¼Í¤Ë¤è¤ë¹¥Ãæµå¤Î³èÀ­²½¤Î»Øɸʬ»Ò¤Î mRNA ¤Îȯ¸½¤Ë¤Ä¤¤¤Æ²òÀϤ·¤¿¡£Æäˡ¢10 Gy ¤Î¦ÃÀþ¾È¼Í¤Ç¤Ï mRNA ¤Î¾å¾º¤¬¤ß¤é¤ì¡¢¹¥Ãæµå¤¬¦ÃÀþ¤Ë¤è¤Ã¤Æ³èÀ­²½¤µ¤ì¤Æ¤¤¤ë¤³¤È¤¬¿äÄꤵ¤ì¤ë¡£ MPO ʬ»Ò¤Ï¡¢Ç®°Ê³°¤Ë¤âÊü¼ÍÀþ¤Ë¤è¤Ã¤Æ¤âÀÚÃǤµ¤ì¤ë¤³¤È¤¬¼¨¤µ¤ì¤¿¤³¤È¤«¤é¡¢Êü¼ÍÀþÈïÇø¤Ë¤è¤Ã¤ÆÀÚÃǤµ¤ì¤¿ MPO ¥Õ¥é¥°¥á¥ó¥È¤ª¤è¤Ó¥ê¥ó¥Ñµå¤Îµ¡Ç½°Û¾ï¤Ë¤è¤Ã¤Æ¡¢MPO ¹³ÂÎ (MPO-ANCA) ¤¬»ºÀ¸¤µ¤ì¤ë²ÄǽÀ­¤¬¹Í¤¨¤é¤ì¤ë¡£
¡¡

¾ÜºÙÀâÌÀ¡¡¡¡¡¡¡¡¡§
¡¡¸ÄÂÎ¥ì¥Ù¥ë¤ÎÊü¼ÍÀþÈïÇø¤Î¥ê¥¹¥¯É¾²Á¤Ë¤Ï¡¢Çò·ìµå¤Î¸º¾¯¤¬»Øɸ¤Ë¤Ê¤Ã¤Æ¤¤¤ë¡£Êü¼ÍÀþ¤Ë¤è¤ëÇò·ìµå¸º¾¯¤Ï¡¢¼ç¤Ë´¶À÷Ëɸæ¤òô¤¤¡¢Áý¿£¤Î®¤¤¹¥Ãæµå¿ô¤Ë±Æ¶Á¤·¤Æ¤¤¤ë¤³¤È¤¬È¿±Ç¤µ¤ì¤Æ¤¤¤ë¡£¤·¤«¤·¡¢¤½¤Îµ¡Ç½¤Ø¤ÎÊü¼ÍÀþ¤Î±Æ¶Á¤Ë¤Ä¤¤¤Æ¤ÏÌÀ¤é¤«¤Ë¤µ¤ì¤Æ¤¤¤Ê¤¤¡£¤Þ¤¿¡¢Êü¼ÍÀþÈïÇø¸å¤Î±Æ¶Á¤È¤·¤Æ¡¢ÈïÇøÀþÎ̤ȥê¥ó¥Ñµå¤ÎÀ÷¿§Âΰ۾ï¤È¤Î´Ø·¸¤Ï¡¢Ëö¾¿·ìÃæ¤Ë»Ä¸¤¹¤ë¥ê¥ó¥Ñµå¤Ë¤ª¤¤¤ÆÄ´¤Ù¤é¤ì¤Æ¤ª¤ê¡¢Êü¼ÍÀþ¤Ë¤è¤ëÀ÷¿§Âΰ۾ï¤ò¤È¤â¤Ê¤¦°äÅÁ»Ò°Û¾ï¤ä¼«¸ÊÌȱּÀ´µ¤ò¤Ï¤¸¤á¤È¤¹¤ëÌȱֵ¡Ç½ÉÔÁ´¤Ï¡¢Êü¼ÍÀþ¤Ë¤è¤ë¥ê¥ó¥Ñµå¤Î°Û¾ï¤ä¹¥Ãæµå¤Ê¤É¤Î¤·ì·ÏºÙ˦¤Îʬ²½°Û¾ï¤Ë¤è¤Ã¤Æ¤¤¤ë¤È¿äÄꤵ¤ì¤Æ¤¤¤ë¡£
¡¡
¡¡¶áǯ¡¢À¸ÂÎËɸæÈ¿±þ¤Î¥Í¥Ã¥È¥ï¡¼¥¯¤Î¥á¥Ç¥£¥¨¡¼¥¿¡¼¤È¤·¤Æ¥¤¥ó¥¿¡¼¥í¥¤¥­¥ó¡¿¥µ¥¤¥È¥«¥¤¥ó¤Î´ØÍ¿¤¬ÌÀ¤é¤«¤Ë¤µ¤ì¡¢ºÙ˦´Ö¤ÎÁê¸ß´Ø·¸¤Î²òÌÀ¤ÏµÞ®¤ËȯŸ¤·¤¿¡£»ç³°Àþ¤Ê¤É¤Ë¤è¤ëÀ¸ÂΤؤαƶÁ¤ÏɽÈéºÙ˦¤ËľÀܱƶÁ¤òÍ¿¤¨¡¢¥µ¥¤¥È¥«¥¤¥óÅù¤Î°ø»Ò¤ÎÈù¾®¤ÊÊѲ½¤òÄ̤¸¤ÆÌȱֺÙ˦¤ËƯ¤­¤«¤±À¸ÂÎËɸ浡ǽ¤òͶȯ¤¹¤ë¤Ê¤É¡¢»ç³°Àþ¤Ë¤è¤ë¥µ¥¤¥È¥«¥¤¥ó¤ÈÌȱֺÙ˦¤Ø¤Î´ØÍ¿¤Ë¤Ä¤¤¤Æ¤ÎÃ諤¬ÆÀ¤é¤ì¤Æ¤­¤Æ¤¤¤ë¡£¥µ¥¤¥È¥«¥¤¥ó¤ÈÌȱֺÙ˦¤Îµ¡Ç½°Û¾ï¤Ë¤è¤Ã¤Æ¼«¸ÊÌȱּÀ´µ¤¬Í¶È¯¤µ¤ì¤ë¤È¹Í¤¨¤é¤ì¤Æ¤ª¤ê¡¢¤½¤Î°ì¤Ä¤Ë¹¥Ãæµå¼«¸Ê¹³ÂÎANCA´ØÏ¢¼«¸ÊÌȱּÀ´µ¤¬ÃíÌܤµ¤ì¤Æ¤¤¤ë¡£¤½¤Î¹³ÂΤÎÂбþʬ»Ò¤Ë¤Ï¡¢¥é¥¤¥½¥¾¡¼¥à¹ÚÁǤÎMyeloperoxidase (MPO)¤¬ÌÀ¤é¤«¤Ë¤µ¤ì¤Æ¤¤¤ë(¸¶ÏÀʸ1¡¼6)¡£
¡¡
¡¡MPO¤òÂбþ¹³¸¶¤È¤¹¤ë¼«¸ÊÌȱּÀ´µ¤Îȯ¾É¤Ë¤ÏMPOʬ»Ò¤ÎÀ¸ÂΤǤθºßÍͼ°¤¬´ØÍ¿¤·¤Æ¤¤¤ë¤â¤Î¤È¿äÄꤵ¤ì¤ë¡£¤³¤ì¤Þ¤Ç¤Ë¡¢MPOʬ»Ò¤ÏÉÔ°ÂÄê¤ÇÇ®¤Ë¤è¤êÀÚÃǤµ¤ì¤ë¤³¤È¤¬¼¨¤µ¤ì¤Æ¤¤¤ë¡£¤ï¤ì¤ï¤ì¤Ï¡¢Ê¬»Ò¤ÎÀÚÃǤª¤è¤ÓÅü¤Î·ë¹ç¤¬¹³ÂΤȤÎÈ¿±þÀ­¤Ë´ØÍ¿¤·¤Æ¤¤¤ë¤³¤È¤ò¼¨¤·¤Æ¤­¤¿(¸¶ÏÀʸ7)¡£MPOʬ»Ò¤ÎÀÚÃǤϡ¢Ç®°Ê³°¤Ë¤âUV¤äÊü¼ÍÀþ¤Ë¤è¤Ã¤Æ¤â¤ª¤³¤ë¤³¤È¤¬¿äÄꤵ¤ì¤ë¤³¤È¤«¤é¡¢Êü¼ÍÀþÈïÇú¤Ë¤è¤ëÀÚÃÇMPO¤ª¤è¤Ó¥ê¥ó¥Ñµå¤Îµ¡Ç½°Û¾ï¤Ë¤è¤Ã¤Æ¡¢MPO¹³ÂÎ(MPO-ANCA)¤¬»ºÀ¸¤¹¤ë¤³¤È¤¬¹Í¤¨¤é¤ì¤ë¡£
¡¡
¡¡Êü¼ÍÀþÈïÇø¤Ëȼ¤¦Çò·ìµåµ¡Ç½¤Î°Û¾ï¤ÎͶȯ¤È¼«¸ÊÌȱּÀ´µÈ¯¾É¤È¤Î´ØÏ¢¤¬»ØŦ¤µ¤ì¤Æ¤¤¤ë¤³¤È¤«¤é(¸¶ÏÀʸ8)¡¢MPOʬ»Ò¹½Â¤¤ÎÊѲ½¤ò»Øɸ¤Ë¤·¤Æ¸¡Æ¤¤¹¤ë¤È¤È¤â¤Ë¡¢³èÀ­²½¹¥Ãæµå¤«¤é¤Î¥é¥¤¥½¥¾¡¼¥à¹ÚÁÇMPO¤ÎÊü½Ð¤ËÂФ¹¤ëÊü¼ÍÀþÈïÇø¤Î±Æ¶Á¤ª¤è¤ÓMPO¤Îʬ»Ò¹½Â¤¤ÎÊѲ½¤Ë¤Ä¤¤¤Æ¸¡Æ¤¤¹¤ë¤³¤È¤¬½ÅÍפʲÝÂê¤Ë¤Ê¤Ã¤Æ¤¤¤ë¡£
¡¡
¡¡¹âÀþÎ̤ÎÊü¼ÍÀþ¾È¼Í¤Ë¤è¤Ã¤Æ¹¥Ãæµå¤ÎMPOʬ»Ò¤Ï¡¢¥Õ¥é¥°¥á¥ó¥È¤Ë¤Ê¤ê³èÀ­¤ÎÄã²¼¤ò¾·¤­¡¢Ê¬²ò¤¬Áᤤ¤ÈͽÁÛ¤µ¤ì¤ë·ë²Ì¤¬ÆÀ¤é¤ì¤Æ¤¤¤ë¡£°ìÊý¡¢3 Gy°Ê²¼¤Î¾È¼Í¤Ç¤Ï¤à¤·¤íʬÈç·¿¤È¤·¤Æ30 kDa¥Õ¥é¥°¥á¥ó¥È¤¬»ºÀ¸¤µ¤ì¡¢ºÙ˦³°¤ËÊü½Ð¤µ¤ì¤ë¤³¤È¤¬Ç§¤á¤é¤ì¤Æ¤¤¤ë¡£¤³¤ì¤é¤Î¤³¤È¤«¤é¡¢MPO¥Õ¥é¥°¥á¥ó¥È¤Ï30 kDa¤È¤·¤ÆʬÈ礵¤ì¡¢¼«¸Ê¹³ÂλºÀ¸¤Ë´ØÍ¿¤·¤Æ¤¤¤ë¤³¤È¤¬Í½ÁÛ¤µ¤ì¤ë¡£°ìÊý¡¢MPO¤ÎºÙ˦³°³èÀ­¤Ï10¡¢30 Gy¤Ç¹âÃͤò¼¨¤·¤Æ¤ª¤ê¡¢Êü½Ðǽ¤ÎÄã²¼¤È¤Ï°Û¤Ê¤Ã¤¿¡Ê¸¶ÏÀʸ9¡¢¿Þ1¡Ë¡£


¿Þ1¡¡¦ÃÀþ¾È¼Í¤Ë¤è¤ë¹¥Ãæµå¤«¤éÊü½Ð¤µ¤ì¤¿ MPO ³èÀ­¡Ê¸¶ÏÀʸ9¤è¤ê°úÍÑ¡Ë

¡¡

¥³¥á¥ó¥È¡¡¡¡¡¡¡¡¡§
¡¡MPO¤ÎÃÇÊÒ¤ò¥ê¥³¥ó¥Ó¥Ê¥ó¥È¤È¤·¤ÆºîÀ®¤·¡¢¥¨¥Ô¥È¡¼¥×¤ò²òÌÀ¤¹¤ëµ»½Ñ¤È¤·¤Æ³«È¯¤·¤¿ÅÀ¤¬Í¥¤ì¤Æ¤¤¤ë¡£¤Þ¤¿¡¢Êü¼ÍÀþ¤Ë¤è¤ëMPOÃÇÊÒ²½¤Ø¤ÎºîÍѤòÄ´¤Ù¤¿ÅÀ¤Ç¿·¤·¤¤Ãθ«¤Ç¤¢¤ë¡£
¡¡

¸¶ÏÀʸ£± Data source 1¡§
MPO-ANCA¡§¹¥ÃæµåºÙ˦¼Á¼«¸Ê¹³Âι¥Ãæµå¡Ýµ¡Ç½Äã²¼¤Èµ¡Ç½Ð¶¿Ê¡Ý
ÎëÌÚÏÂÃË
¹ñΩ´¶À÷¾É¸¦µæ½ê
ºûÅľ»¹§ÊÔ, °åÌô¥¸¥ã¡¼¥Ê¥ë¼Ò, pp.194-219, 1998.

¸¶ÏÀʸ£² Data source 2¡§
ÁíÀâ¡Ö¹¥ÃæµåºÙ˦¼Á¼«¸Ê¹³ÂÎ(ANCA)¤ÈÁÈ¿¥µ¡Ç½¾ã³²¡ÝMPO-ANCA¤òÃæ¿´¤Ë¡×
ÎëÌÚÏÂÃË
¹ñΩ´¶À÷¾É¸¦µæ½ê
Î×¾²±Ö³Ø, 30, 358-369 (1998).

¸¶ÏÀʸ£³ Data source 3¡§
ÁíÀâ¡Ö­¼¡¥ÌȱּÀ´µ 2. ¹¥ÃæµåºÙ˦¼Á¼«¸Ê¹³ÂΡÝANCA¡Ý
ÎëÌÚÏÂÃË
¹ñΩ´¶À÷¾É¸¦µæ½ê
Ãæ³°°å³Ø¼Ò, 1997, pp. 266-278 (1997), Annual Review 1998.

¸¶ÏÀʸ£´ Data source 4¡§
Serum myeloperoxidase and serum cytokines in a anti-myeloperoxidase antibody associated glomerulonephritis
Y. Arimura, S. Minoshima, Y. Kamiya, K. Nakabayashi, K. Kitamoto, T. Nagasawa, T. Sasaki, and K. Suzuki
¹ñΩ´¶À÷¾É¸¦µæ½ê
Clin. Nephrol., 40, pp. 256-264 (1993).

¸¶ÏÀʸ£µ Data source 5¡§
T. Saeki, T.Kuroda, T. Morita, K. Suzuki, M. Arakawa, and K. Kawasaki
Significance of myeloperoxidase in rapidly progressive glomerulonephritis
¹ñΩ´¶À÷¾É¸¦µæ½ê
Am. J. Kidney Dis., 26, pp. 13-21 (1995).

¸¶ÏÀʸ£¶ Data source 6¡§
Tomizawa K., Mine E., Fuji A., Ohashi Y., Yamagoe S., Ishida-Okawara A., Hashimoto Y., Ito M., Tanokura M., Yamamoto T., Arimura Y., Nagasawa T., Mizuno S., and Suzuki K.
A panel set for epitope analysis of myeloperoxidase(MPO)-specific anti-neutrophil cytoplasmic antibody MPO-ANCA using recombinant hexamer histidine-tagged MPO Deletion Mutants
¹ñΩ´¶À÷¾É¸¦µæ½ê
J. Clin. Immunol., 18, pp.142-152 (1998).

¸¶ÏÀʸ£· Data source 7¡§
Otani I., Ishida-Okawara A., Yamagoe S., Miyoshi-Koshio T., Arimura Y., Nagasawa T., Mizuno S., and Suzuki K.
Myeloperoxidase(MPO) fragments reacting with a serum of patient with MPO-ANCA positive glomerulonephritis
¹ñΩ´¶À÷¾É¸¦µæ½ê
J. Infect. Chemother., 3, pp.164-169 (1997).

¸¶ÏÀʸ£¸ Data source 8¡§
Fujiwara S., Carter R.L., Akiyama M., Akahoshi M., Sasaki H., Yamada M., Neriishi K., Kusumi S., Kodama K., Shimooka K., and Yamakido M.
Autoantibodies and immunoglobulins among atomic-bomb survivors
Êü¼ÍÀþ±Æ¶Á¸¦µæ½ê
RERF Tech. Rep., pp. 4-92 (1992).

¸¶ÏÀʸ£¹ Data source 9¡§
Êü¼ÍÀþÈïÇø¤Ë¤è¤ë¼«¸ÊÌȱּÀ´µ¤ÎͶȯ¡§¹¥Ãæµå¥ß¥¨¥í¥Ñ¡¼¥ª¥­¥·¥Ç¡¼¥¹¤Îʬ»Ò¹½Â¤¤ÎÊѲ½
ÎëÌÚÏÂÃË¡¤ÂçÀÊþ»Ò¡¤¶¶Ëܤ椭¡¤»³±ÛÃÒ¡¤Niels Borregaad¡¤¿åÌÉÒ
¹ñΩ´¶À÷¾É¸¦µæ½ê¡¡À¸Êª³èÀ­Êª¼ÁÉô
Ê¿À® 9ǯÅÙ¹ñΩµ¡´Ø¸¶»ÒÎϻ¸¦µæÀ®²ÌÊó¹ð½ñ, pp.102-1¡Á102-4, Ê¿À® 8ǯÅÙ¡ÁÊ¿À®10ǯÅÙ (1998).

¥­¡¼¥ï¡¼¥É¡§¥¬¥ó¥ÞÀþ¡¢¥ß¥¨¥í¥Ñ¡¼¥ª¥­¥·¥Ç¡¼¥¹(MPO)¡¢¹¥Ãæµå¼«¸Ê¹³ÂÎ(MPO-ANCA)¡¢MPO¤ÎÃÇÊÒ²½¡¢·ì´É±ê
gamma-ray¡¢myeloperoxidase(MPO)¡¢anti-neutrophil antibody(MPO-ANCA)¡¢fragmentation of MPO¡¢vasculitis
ʬÎॳ¡¼¥É¡§150401

¸¶»ÒÎÏ´ðÈ×µ»½Ñ¥Ç¡¼¥¿¥Ù¡¼¥¹¤Î¥á¥¤¥ó¥Ú¡¼¥¸¤Ø